Optimizing Immunomodulators and Anti-TNF Agents in the Therapy of Crohn Disease

Gastroenterology Clinics of North America

Volumn 41, Issue 2, 2012, Pages 393-409

  Dassopoulos, Themistocles ^a   Sninsky, Charles A ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Digestive Disease Associates   (United States)

Author keywords

6 thioguanine nucleotides; 6 mercaptopurine; Azathioprine; Crohn disease; Infliximab; Thiopurine methyltransferase

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; 6 METHYLTHIOINOSINE; ADALIMUMAB; ALLOPURINOL; AZATHIOPRINE; CERTOLIZUMAB PEGOL; INFLIXIMAB; MERCAPTOPURINE; PLACEBO; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIBODY PRODUCTION; BONE MARROW SUPPRESSION; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; ENTERITIS; ENZYME ACTIVITY; HUMAN; IMMUNOGENICITY; INFECTION; LEUKOPENIA; LIVER TOXICITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHYLTRANSFERASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859637808     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2012.01.004     Document Type: Review

References (84)

1. Sahasranaman S., Howard D., Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008, 64:753.
2. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992, 43:329.
3. Weinshilboum R.M., Sladek S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980, 32:651.
4. Lennard L. Thiopurine methyltransferase in the treatment of Crohn's disease with azathioprine. Gut 2002, 51:143.
5. Ansari A., Arenas M., Greenfield S.M., et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008, 28:973.
6. Ansari A., Hassan C., Duley J., et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002, 16:1743.
7. Cuffari C., Dassopoulos T., Turnbough L., et al. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004, 2:410.
8. Dubinsky M.C., Lamothe S., Yang H.Y., et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118:705.
9. Lowry P.W., Franklin C.L., Weaver A.L., et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001, 49:665.
10. Gardiner S.J., Gearry R.B., Begg E.J., et al. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin Gastroenterol Hepatol 2008, 6:654.
11. Gonzalez-Lama Y., Bermejo F., Lopez-Sanroman A., et al. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther 2011, 34:544.
12. Winter J.W., Gaffney D., Shapiro D., et al. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2007, 25:1069.
13. Colombel J.F., Ferrari N., Debuysere H., et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000, 118:1025.
14. Gisbert J.P., Luna M., Mate J., et al. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Hepatogastroenterology 2006, 53:399.
15. Lichtenstein G.R., Abreu M.T., Cohen R., et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130:940.
16. Travis S.P., Stange E.F., Lemann M., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006, 55(Suppl 1):i16.
17. Imuran (azathioprine) [package insert] 2009, Prometheus Laboratories I, San Diego (CA).
18. Dubinsky M.C., Yang H., Hassard P.V., et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002, 122:904.
19. Sparrow M.P., Hande S.A., Friedman S., et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007, 5:209.
20. Goldenberg B.A., Rawsthorne P., Bernstein C.N. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol 2004, 99:1744.
21. Winter J., Walker A., Shapiro D., et al. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2004, 20:593.
22. Priest V.L., Begg E.J., Gardiner S.J., et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics 2006, 24:767.
23. Smith M.A., Marinaki A.M., Sanderson J.D. Pharmacogenomics in the treatment of inflammatory bowel disease. Pharmacogenomics 2010, 11:421.
24. Osterman M.T., Kundu R., Lichtenstein G.R., et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006, 130:1047.
25. Dassopoulos T., Martin C.F., Galanko J., et al. A Randomized trial of metabolite-adjusted versus weight-based dosing of azathioprine (AZA) in Crohn's disease (CD). Gastroenterology 2009, 136. A-519.
26. Reinshagen M., Schutz E., Armstrong V.W., et al. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. Clin Chem 2007, 53:1306.
27. Nygaard U., Toft N., Schmiegelow K. Methylated metabolites of 6-MP are associated with hepatotoxicity. Clin Pharmacol Ther 2004, 75:274.
28. Ansari A., Elliott T., Baburajan B., et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008, 28:734.
29. Govani S.M., Higgins P.D. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. J Crohns Colitis 2010, 4:444.
30. Rahhal R.M., Bishop W.P. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008, 14:1678.
31. Blaker P.A., Monica Arenas A., Fairbanks L., et al. A Biochemical mechanism for the role of allopurinol in TPMT inhibition. Gastroenterology 2011, 140. S-769.
32. Haines M.L., Ajlouni Y., Irving P.M., et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 2011, 17:1301.
33. Danese S., Sans M., Scaldaferri F., et al. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol 2006, 176:2617.
34. Horiuchi T., Mitoma H., Harashima S., et al. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 2010, 49:1215.
35. Nesbitt A., Fossati G., Bergin M., et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007, 13:1323.
36. Van den Brande J.M., Braat H., van den Brink G.R., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003, 124:1774.
37. Arijs I., De Hertogh G., Machiels K., et al. Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. Am J Gastroenterol 2011, 106:748.
38. Li Z., Arijs I., De Hertogh G., et al. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. Inflamm Bowel Dis 2010, 16:1299-1310.
39. Veltkamp C., Anstaett M., Wahl K., et al. Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFalpha treatment. Gut 2011, 60:1345.
40. Vos A.C., Wildenberg M.E., Duijvestein M., et al. Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology 2011, 140:221.
41. Ternant D., Aubourg A., Magdelaine-Beuzelin C., et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008, 30:523.
42. Fasanmade A.A., Adedokun O.J., Blank M., et al. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther 2011, 33:946.
43. Fasanmade A.A., Adedokun O.J., Ford J., et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 2009, 65:1211.
44. van der Laken C.J., Voskuyl A.E., Roos J.C., et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 2007, 66:253.
45. Fasanmade A.A., Adedokun O.J., Olson A., et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 2010, 48:297.
46. Klotz U., Teml A., Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007, 46:645.
47. Vermeire S., Van Assche G., Rutgeerts P. Role of genetics in prediction of disease course and response to therapy. World J Gastroenterol 2010, 16:2609.
48. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541.
49. Hanauer S.B., Wagner C.L., Bala M., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542.
50. Karmiris K., Paintaud G., Noman M., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628.
51. Lichtenstein G.R., Thomsen O.O., Schreiber S., et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol 2010, 8:600.
52. Sandborn W.J., Feagan B.G., Stoinov S., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007, 357:228.
53. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007, 357:239.
54. Vermeire S., Noman M., Van Assche G., et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007, 56:1226.
55. Maser E.A., Villela R., Silverberg M.S., et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248.
56. Rutgeerts P., Feagan B.G., Lichtenstein G.R., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402.
57. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's Disease. N Engl J Med 2003, 348:601.
58. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52.
59. Hanauer S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323.
60. Targan S.R., Hanauer S.B., van Deventer S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2. N Engl J Med 1997, 337:1029. Study Group.
61. Schreiber S., Colombel J.F., Bloomfield R., et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 2010, 105:1574.
62. Billioud V., Sandborn W.J., Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011, 106:674.
63. Chaparro M., Panes J., Garcia V., et al. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. J Clin Gastroenterol 2011, 45:113.
64. Rudolph S.J., Weinberg D.I., McCabe R.P. Long-term durability of Crohn's disease treatment with infliximab. Dig Dis Sci 2008, 53:1033.
65. Rutgeerts P., D'Haens G., Targan S., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999, 117:761.
66. Yanai H., Hanauer S.B. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011, 106:685.
67. Loftus E.V., Pan X., Zurawski P., et al. Adalimumab real-world dosage pattern and predictors of weekly dosing: Patients with Crohn's disease in the United States. J Crohns Colitis 2011, 5:550-554.
68. Ainsworth M.A., Bendtzen K., Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008, 103:944.
69. Steenholdt C., Bendtzen K., Brynskov J., et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011, 46:310.
70. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383.
71. Bendtzen K., Geborek P., Svenson M., et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006, 54:3782.
72. Mulleman D., Chu Miow Lin D., Ducourau E., et al. Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. Ther Drug Monit 2010, 32:232.
73. St Clair E.W., Wagner C.L., Fasanmade A.A., et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:1451.
74. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007, 66:921.
75. Radstake T.R., Svenson M., Eijsbouts A.M., et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1739.
76. West R.L., Zelinkova Z., Wolbink G.J., et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008, 28:1122.
77. Li J.L., Paulson S.K., Chiu Y.L., et al. Evaluation of potential correlations between serum adalimumab concentration and remission in patients with Crohn's disease in classic I and II. Gastroenterology 2010, 138. S-101.
78. Parsi M.A., Achkar J.P., Richardson S., et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002, 123:707.
79. D'Haens G.R., Panaccione R., Higgins P.D., et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. Am J Gastroenterol 2011, 106:199.
80. Panaccione R., Ghosh G., Middleton M., et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC Success Trial. Gastroenterology 2011, 140:S.
81. Afif W., Loftus E.V., Faubion W.A., et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010, 105:1133.
82. Lemann M., Mary J.Y., Duclos B., et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006, 130:1054.
83. Lemann M., Mary J.Y., Colombel J.F., et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005, 128:1812.
84. Treton X., Bouhnik Y., Mary J.Y., et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009, 7:80.